NCT03379493 - Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

December 23, 2018

Study Completion Date

January 30, 2019

Conditions

Lymphomas Non-Hodgkin's B-Cell

Interventions

BIOLOGICAL

ET190L1 ARTEMIS™ T cells

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion

Trial Locations (1)

27710

Duke University Medical Center, Durham